World-first psilocybin clinical trial in the treatment of Generalised Anxiety Disorder receives ethics approval
This Australian university just got the go-ahead to conduct a first-of-its-kind study!
Yesterday, Monash University received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).
Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).
The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.